Table 1 Comparison of clinicopathological characteristics between SLIT2 hypermethylated and non-hypermethylated CML patients
From: SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
Patients’ parameters | SLIT2 promoter non-hypermethylated (n = 77) | SLIT2 promoter hypermethylated (n = 27) | P value |
|---|---|---|---|
Sex, male/female | 50/27 | 15/12 | 0.489 |
Median age, years (range) | 51 (15–88) | 46 (20–75) | 0.680 |
Median WBC, × 109/L (range) | 128.4 (31.5–413.8) | 41.6 (21.7–293.4) |  < 0.001 |
Median hemoglobin, g/L (range) | 101 (57–146) | 92 (50–152) | 0.277 |
Median platelet, × 109/L (range) | 387 (22–1489) | 250 (16–914) | 0.006 |
Karyotype | Â | Â | 0.438 |
t(9;22) | 53 (69%) | 14 (52%) | Â |
t(9;22) with additional alteration | 10 (13%) | 4 (15%) | Â |
Normal karyotype | 4 (5%) | 3 (11%) | Â |
No data | 10 (13%) | 6 (22%) | Â |
Clinical stage |  |  |  < 0.001 |
CP | 68 (88%) | 12 (44%) | Â |
AP | 4 (5%) | 4 (15%) | Â |
BC | 5 (7%) | 11 (41%) | Â |
BCR::ABL1 transcript (relative copy) | 210 (16.9–3784.8) | 239.1 (13.8–14464.7) | 0.366 |